K. Schalper

PROFILE

Homepage
No homepage is listed.
ORCID
No ORCID is listed.
Affiliations
No affiliations are listed.
Aliases
K. A. Schalper, K. Schalper, Kurt Schalper, Kurt Alex Schalper, Kurt A Schalper, Kurt A. Schalper, K.a. Schalper
Publication record
272 papers · 20,637 citations · H-index 68

PAPERS

IL-4 mediated TAP2 downregulation is a dominant and reversible mechanism of immune evasion and immunotherapy resistance in non-small cell lung cancer
20256 citationsauthor #10
High MGMT expression identifies aggressive colorectal cancer with distinct genomic features and immune evasion properties
20251 citationsauthor #10
TRLS-11 UNCOVERING ANTIGEN-SPECIFICITY OF INTRATUMORAL CD8+ T CELLS IN NON-SMALL CELL LUNG CANCER BRAIN METASTASES
20250 citationsauthor #13
Spatial signatures for predicting immunotherapy outcomes using multi-omics in non-small cell lung cancer
20259 citationsauthor #12
MET (c-Met) protein overexpression is an emerging protein biomarker in non-small cell lung cancer
20252 citationsauthor #7
Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI)
20250 citationsauthor #48
Abstract 4654: Clinical significance of tumor infiltrating lymphocytes and neoadjuvant chemotherapy in colorectal cancer liver metastases
20250 citationsauthor #6
Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition
202588 citationsauthor #32
515 Tumor agnostic spatially defined immune cell gene signatures predict immunotherapy outcomes
20250 citationsauthor #4
spEMO: Leveraging Multi-Modal Foundation Models for Analyzing Spatial Multi-Omic and Histopathology Data
20255 citationsauthor #7
The tumor microenvironment of non–small cell lung cancer impairs immune cell function in people with HIV
20256 citationsauthor #13
Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
20252 citationsauthor #27
Molecular Tumor Boards: A consensus statement from the International Association for the Study of Lung Cancer.
20255 citationsauthor #9
Society for Immunotherapy of Cancer: updates and best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) image analysis and data sharing
20259 citationsauthor #23
Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy: a multidimensional approach
202547 citationsauthor #6
A phase 2 study of olaparib in IDH1 and IDH2 mutant advanced chondrosarcomas and other solid tumors.
20250 citationsauthor #18
Clinical features associated with an exceptional response to immunotherapy in patients with metastatic non-small cell lung cancer (NSCLC).
20250 citationsauthor #4
A phase 2 study of the olaparib and AZD6738, an ATM/ATR inhibitor, in isocitrate dehydrogenase (IDH) mutant solid tumors.
20250 citationsauthor #13
SITC vision: Opportunities for deeper understanding of mechanisms of anti-tumor activity, toxicity, and resistance to optimize cancer immunotherapy
20254 citationsauthor #11
Distinct genomic and immunologic tumor evolution in germline TP53-driven breast cancers
20244 citationsauthor #17
Biomarker development for PD-(L)1 axis inhibition: a consensus view from the SITC Biomarkers Committee
202411 citationsauthor #5
Abstract 6732: Immunomodulatory and anti-tumor effect of a CCR2-targeted STING agonist iADC in human lung cancer
20241 citationsauthor #8
Spatially resolved tissue imaging to analyze the tumor immune microenvironment: beyond cell-type densities
20249 citationsauthor #7
High-throughput transcriptome profiling indicates ribosomal RNAs to be associated with resistance to immunotherapy in non-small cell lung cancer (NSCLC)
202411 citationsauthor #9
Mechanisms of immunotherapy resistance in small cell lung cancer
20248 citationsauthor #2
Abstract 101: A novel humanized mouse model recapitulates the unique TME found in patients with HIV-associated NSCLC
20240 citationsauthor #11
Quantitative Measurement of HER2 Expression in Non-Small Cell Lung Cancer with a High Sensitivity Assay.
20243 citationsauthor #8
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
2024108 citationsauthor #48
Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity
202419 citationsauthor #25
SORBET: Automated cell-neighborhood analysis of spatial transcriptomics or proteomics for interpretable sample classification via GNN
20243 citationsauthor #7
BCAM (basal cell adhesion molecule) protein expression in different tumor populations
20244 citationsauthor #5
Vascular mimicry as a facilitator of melanoma brain metastasis
202410 citationsauthor #7
HLA class-I antigen presentation machinery (APM) alterations mediate immune evasion in lung cancer brain metastases.
20240 citationsauthor #11
Abstract 4893: Role of MGMT expression in the genomic landscape and immunogenicity in human colorectal carcinomas
20240 citationsauthor #10
Differentiating separate primary lung adenocarcinomas from intrapulmonary metastases with emphasis on pathological and molecular considerations: Recommendations from the IASLC Pathology Committee.
202414 citationsauthor #43
International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.
202328 citationsauthor #27
Role of HLA class-I antigen peptide loading complex components in immune evasion and treatment sensitivity in human lung cancer.
20230 citationsauthor #4
Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer
202329 citationsauthor #19
Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer
2023129 citationsauthor #29
Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial
202315 citationsauthor #21
Abstract 1841: TAK-500 is a clinical stage immune-cell directed antibody drug conjugate (iADC) inducing STING activation in CCR2-expressing intratumor myeloid cells and favorable immunomodulation
20232 citationsauthor #1
Digital spatial profiling of melanoma shows CD95 expression in immune cells is associated with resistance to immunotherapy
20237 citationsauthor #8
Objective analysis and clinical significance of the spatial tumor infiltrating lymphocyte patterns in non-small cell lung cancer (NSCLC).
202313 citationsauthor #11
Triangular Analysis of Geographical Interplay of Lymphocytes (TriAnGIL): Predicting Immunotherapy Response in Lung Cancer
20230 citationsauthor #5
Quantitative DNA Repair Biomarkers and Immune Profiling for Temozolomide and Olaparib in Metastatic Colorectal Cancer
20234 citationsauthor #16
Nivolumab and ipilimumab in advanced non small cell lung cancer previously treated with PD1 axis inhibition.
20231 citationsauthor #14
Developing a definition of immune exclusion in cancer: results of a modified Delphi workshop
202328 citationsauthor #16
The β_1-adrenergic receptor links sympathetic nerves to T cell exhaustion
2023166 citationsauthor #16
Abstract CT145: Olaparib +/- atezolizumab in patients with BRCA-mutated (BRCAmt) locally advanced unresectable or metastatic (advanced) breast cancer: an open-label, multicenter, randomized phase II trial
20239 citationsauthor #25
Abstract 3468: Immunoproteasome expression and checkpoint blockade response in advanced non-small cell lung cancer
20230 citationsauthor #29
BSBM-16 HLA CLASS-I ANTIGEN PRESENTATION MACHINERY AND IFN-γ PATHWAY ALTERATIONS IN LUNG CANCER BRAIN METASTASES
20230 citationsauthor #5
Spatial Analysis Reveals Impaired Immune Cell Function within the Tumor Microenvironment of HIV-associated Non-small Cell Lung Cancer
20230 citationsauthor #10
Abstract 6762: Tumor immune microenvironment &genomic features of non-small cell lung carcinomas in patients with HIV (PWH)
20230 citationsauthor #13
NCI 7977: A Phase I Dose-Escalation Study of Intermittent Oral ABT-888 (Veliparib) plus Intravenous Irinotecan Administered in Patients with Advanced Solid Tumors
20233 citationsauthor #9
Neuroendocrine lineage commitment of small cell lung cancers can be leveraged into p53-independent non-cytotoxic therapy
20234 citationsauthor #5
Molecular predictors and immunomodulatory role of dual checkpoint inhibitor blockade using ipilimumab/nivolumab in patients with extensive stage small cell lung cancer.
20231 citationsauthor #16
Spatially resolved proteomic profiling identifies tumor cell CD44 as a biomarker associated with sensitivity to PD-1 axis blockade in advanced non-small-cell lung cancer
202233 citationsauthor #15
PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.
2022926 citationsauthor #31
P2.12-01 Intratumoral Conventional Type 1 Dendritic Cells (cDC1s) Predict Response to Immunotherapy in Human Non-small Cell Lung Cancer cancer (NSCLC)
20220 citationsauthor #9
Abstract 3580: Integrative genomics of checkpoint blockade response in advanced non-small cell lung cancer
20220 citationsauthor #26
RASGRF1 Fusions Activate Oncogenic RAS Signaling and Confer Sensitivity to MEK Inhibition.
202212 citationsauthor #11
2MO First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) in metastatic non-small cell lung cancer (mNSCLC): Clinical outcomes and biomarker analyses from CheckMate 592
20220 citationsauthor #14
Immunologic Analysis Of Non-Small Cell Lung Cancer In People Living With Hiv
20220 citationsauthor #5
Tumor cell SYK expression modulates the tumor immune microenvironment composition in human cancer via TNF-α dependent signaling
202217 citationsauthor #11
Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
2022260 citationsauthor #26
Discovery of biomarkers of resistance to immune checkpoint blockade in non-small-cell lung cancer (NSCLC) using high-plex digital spatial profiling.
202224 citationsauthor #11
Abstract 1722: Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer (NSCLC)
20220 citationsauthor #16
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
2022101 citationsauthor #16
A pilot study of ipilimumab and nivolumab in recurrent extensive-stage small cell lung cancer after platinum-based chemotherapy.
20221 citationsauthor #15
Density patterns of tumor-infiltrating lymphocytes and association with objective response to nivolumab in patients with lung adenocarcinoma from CheckMate 057.
20221 citationsauthor #13
OA09.04 Spatial Mapping and Clinical Significance of the LAG-3/FGL1 Pathway in Non-small Cell Lung Cancer Using High-Dimensional Tissue Imaging
20221 citationsauthor #4
Image analysis reveals molecularly distinct patterns of TILs in NSCLC associated with treatment outcome
202244 citationsauthor #18
Spatial interplay patterns of cancer nuclei and tumor-infiltrating lymphocytes (TILs) predict clinical benefit for immune checkpoint inhibitors
202273 citationsauthor #11
Quantitative tissue analysis and role of myeloid cells in non-small cell lung cancer
20229 citationsauthor #13
HIV is associated with poor overall survival among head and neck cancer patients.
20229 citationsauthor #10
Patients with HIV-associated cancers have evidence of increased T cell dysfunction and exhaustion prior to cancer diagnosis
202218 citationsauthor #13
Integrative Analysis of Checkpoint Blockade Response in Advanced Non-Small Cell Lung Cancer
20221 citationsauthor #28
Abstract 2028: Spatially resolved proteomic profiling identifies tumor cell CD44 as a novel indicative biomarker of sensitivity to PD-1 axis blockade in advanced non-small cell lung cancer (NSCLC)
20220 citationsauthor #15
Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective from the IASLC Pathology Committee.
2022150 citationsauthor #2
148 TAP2 deficiency mediates adaptive immune evasion and immunotherapy resistance in human non-small cell lung cancer
20220 citationsauthor #6
A burned-out CD8+ T-cell subset expands in the tumor microenvironment and curbs cancer immunotherapy.
2021110 citationsauthor #21
Association of PD-1/PD-L1 Co-location with Immunotherapy Outcomes in Non–Small Cell Lung Cancer
202118 citationsauthor #8
Spatially resolved analysis of the T cell immune contexture in lung cancer-associated brain metastases
202120 citationsauthor #12
Heterogenous presence of neutrophil extracellular traps in human solid tumours is partially dependent on IL‐8
202189 citationsauthor #5
Targeting the Atf7ip–Setdb1 Complex Augments Antitumor Immunity by Boosting Tumor Immunogenicity
202133 citationsauthor #26
Tumour antigen-induced T cell exhaustion — the archenemy of immune-hot malignancies
202130 citationsauthor #2
Spatial Mapping and Immunomodulatory Role of the OX40/OX40L Pathway in Human Non–Small Cell Lung Cancer
202126 citationsauthor #8
P15.04 A Phase I/IB Trial of Pembrolizumab and Trametinib Focused on Advanced KRAS Mutant Non-Small Cell Lung Cancer
20211 citationsauthor #2
Spatial Analysis and Clinical Significance of HLA Class-I and Class-II Subunit Expression in Non–Small Cell Lung Cancer
202122 citationsauthor #11
Tumor Microenvironment: Immune Effector and Suppressor Imbalance
20210 citationsauthor #2
Abstract LB197: An SU2C-Mark Foundation Lung collaborative update: integrative genomics identifies distinct transcriptional states associated with checkpoint blockade resistance
20210 citationsauthor #24
Abstract 418: Lower survival among HIV-infected head and neck cancer patients
20210 citationsauthor #6
Biomarker Discovery in Patients with Immunotherapy-Treated Melanoma with Imaging Mass Cytometry
202146 citationsauthor #8
NTRK genomic alterations in Latin-American cancer patients.
20210 citationsauthor #7
Effects of Radiation on the Tumor Microenvironment.
202068 citationsauthor #2
Overview of Lung Cancer Immunotherapy
202010 citationsauthor #3
Compactness measures of tumor infiltrating lymphocytes in lung adenocarcinoma are associated with overall patient survival and immune scores
20206 citationsauthor #11
The Society for Immunotherapy in Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation
2020208 citationsauthor #15
Pembrolizumab for management of patients with NSCLC and brain metastases: long-term results and biomarker analysis from a non-randomised, open-label, phase 2 trial.
2020398 citationsauthor #2
IA11 Role of the Tumor Microenvironment in Sensitivity and Resistance to Immunostimulatory Therapies in NSCLC
20200 citationsauthor #1

TIMELINE

2007 223 citations

2008 183 citations

2009 258 citations

2010 336 citations

2011 65 citations

2012 99 citations

2013 282 citations

2014 2,043 citations

2015 668 citations

2016 1,669 citations

2017 2,047 citations

2018 2,932 citations

2019 4,501 citations

2020 2,287 citations

2021 395 citations

2022 1,680 citations

2023 439 citations

2024 205 citations

2025 184 citations

Unknown 23 citations

K. Schalper

PROFILE

PAPERS

TIMELINE

COAUTHOR MAP

CONCEPT FOOTPRINT